{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MCG&page=18",
    "query": {
      "intervention": "MCG",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 3096,
    "total_pages": 310,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MCG&page=19&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MCG&page=17&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T17:06:59.064Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03686618",
      "title": "Secretin for Acute Pancreatitis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatitis, Acute"
      ],
      "interventions": [
        {
          "name": "Secretin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ChiRhoClin, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2018-10-01",
      "completion_date": "2019-11-01",
      "has_results": false,
      "last_update_posted_date": "2019-04-10",
      "last_synced_at": "2026-10-26T17:06:59.064Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03686618"
    },
    {
      "nct_id": "NCT05363618",
      "title": "Tolerability Study of Panosyl-Isomaltooligosaccharides (PIMO) and a Placebo in Subjects With Heartburn",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Heartburn"
      ],
      "interventions": [
        {
          "name": "Panosyl-isomaltooligosaccharides (PIMO) 1g (1.4 ml)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo 1.4 ml",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Microbiome Health Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 211,
      "start_date": "2022-02-10",
      "completion_date": "2023-05-30",
      "has_results": false,
      "last_update_posted_date": "2023-07-18",
      "last_synced_at": "2026-10-26T17:06:59.064Z",
      "location_count": 1,
      "location_summary": "Manassas, Virginia",
      "locations": [
        {
          "city": "Manassas",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05363618"
    },
    {
      "nct_id": "NCT00694590",
      "title": "Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia (CLL)",
        "Small Lymphocytic Lymphoma (SLL)"
      ],
      "interventions": [
        {
          "name": "plerixafor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 24,
      "start_date": "2008-06",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2015-03-20",
      "last_synced_at": "2026-10-26T17:06:59.064Z",
      "location_count": 3,
      "location_summary": "La Jolla, California • Columbus, Ohio • Houston, Texas",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00694590"
    },
    {
      "nct_id": "NCT04019574",
      "title": "Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "CR845 0.5 mcg/kg IV",
          "type": "DRUG"
        },
        {
          "name": "CR845 3 mcg/kg IV",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin 400 mg Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Cara Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 57,
      "start_date": "2019-06-20",
      "completion_date": "2019-10-29",
      "has_results": false,
      "last_update_posted_date": "2020-02-21",
      "last_synced_at": "2026-10-26T17:06:59.064Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04019574"
    },
    {
      "nct_id": "NCT00074490",
      "title": "Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma",
        "Leukemia",
        "Myeloproliferative Disorders",
        "Multiple Myleoma",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Peripheral blood stem cell (PBSC) transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells",
          "type": "GENETIC"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic hematopoietic stem cell transplant (HSCT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        },
        {
          "name": "T-Rapa cell Donor Lymphocyte Infusion (DLI)",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "GENETIC"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "11 Years to 90 Years"
      },
      "enrollment_count": 442,
      "start_date": "2004-01-01",
      "completion_date": "2017-08-16",
      "has_results": true,
      "last_update_posted_date": "2018-12-31",
      "last_synced_at": "2026-10-26T17:06:59.064Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Hackensack, New Jersey",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00074490"
    },
    {
      "nct_id": "NCT00597818",
      "title": "Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NSAID-induced Gastroduodenal Injury",
        "Ulcers",
        "Rheumatoid Arthritis",
        "Osteoarthritis"
      ],
      "interventions": [
        {
          "name": "Cobiprostone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Non-steroidal anti-inflammatory drug",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sucampo Pharma Americas, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 121,
      "start_date": "2007-08",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2019-12-26",
      "last_synced_at": "2026-10-26T17:06:59.064Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Chula Vista, California • Loma Linda, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00597818"
    },
    {
      "nct_id": "NCT01871727",
      "title": "A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Persistent or Recurrent Cutaneous T-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "E7777 9 mcg/kg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 112,
      "start_date": "2013-05-30",
      "completion_date": "2021-12-14",
      "has_results": true,
      "last_update_posted_date": "2024-11-13",
      "last_synced_at": "2026-10-26T17:06:59.064Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01871727"
    },
    {
      "nct_id": "NCT02683369",
      "title": "Low-dose Iron Supplementation and Markers of Iron Status Among Non-anemic, Iron-deficient Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Non-anemic Iron Deficiency"
      ],
      "interventions": [
        {
          "name": "Blood Builder®/Iron Response®",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 55 Years · Female only"
      },
      "enrollment_count": 23,
      "start_date": "2016-02",
      "completion_date": "2017-05",
      "has_results": false,
      "last_update_posted_date": "2019-08-16",
      "last_synced_at": "2026-10-26T17:06:59.064Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02683369"
    },
    {
      "nct_id": "NCT01283022",
      "title": "Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Ripening",
        "Induction of Labor"
      ],
      "interventions": [
        {
          "name": "MVI 200",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ferring Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2011-05",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2014-04-14",
      "last_synced_at": "2026-10-26T17:06:59.064Z",
      "location_count": 1,
      "location_summary": "Pasadena, California",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01283022"
    },
    {
      "nct_id": "NCT01852513",
      "title": "Allergic Rhinitis Changes the Sinus Microbiome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Seasonal Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "QNASL",
          "type": "DRUG"
        },
        {
          "name": "Placebo nasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 39,
      "start_date": "2013-01",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2020-10-09",
      "last_synced_at": "2026-10-26T17:06:59.064Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01852513"
    }
  ]
}